Program​​​​​​​​​​​

QSPC2026

• The QSPC2026 program will consist of 11 plenary sessions with invited speakers from both academia and industry, with contributions from key opinion leaders as well as emerging investigators.The program will include several tutorial sessions on key emerging techniques and approaches in QSP.

• QSPC will offer ample opportunities for scientific exchange and networking, through poster sessions, plenary trainee flash talks, social activities, tutorials, software demonstrations by exhibitors, and satellite workshops.

• Conference schedule

  Date	Time	Event
  April 7, 2026	17:00 - 19:00	Welcome reception
  April 8, 2026	08:30 - 18:00	Scientific program
  	19:00 - 23:00	Social event
  April 9, 2026	08:30 - 18:00	Scientific program
  April 10, 2026	09:00 - 13:00	Scientific program

Scientific program

DAY 1: Wednesday, April 8, 2026

08:30 – 08:45 | Welcome & Opening Remarks

08:45 – 10:05 | Session 1: New Rules, New Models: Quantitative Science for Emerging Modalities

Chairs: Don Mager (University at Buffalo) & Tamara van Steeg (LAP&P)

• Modeling the Disposition of Oligonucleotide Therapeutics (ASOs and GalNAc-siRNA) in Preclinical Species and Humans — Rodrigo Cristofoletti (University of Florida)

• Navigating complexity: Opportunities and challenges in translational oncolytic virus modeling — Zinnia Para-Guillen (BioInvent/Univ Navarra)

• A translational mechanistic-QSP framework for predicting protein expression with mRNA therapeutics and vaccines — Rajat Desikan (GSK)

• Flash Talk

10:05 – 10:50 | Coffee Break

10:50 – 12:10 | Session 2: QSP and AI/ML: Current Opportunities and Future Vision

Chairs: Robert Bies (University at Buffalo) & Sandra Visser (Quantivis LLC)

• Improving precision through hybrid ML and QSP modeling: an example in immuno-oncology — Anna Kondic (Bristol Myers Squibb)

• Addressing the QSP Knowledge Bottleneck with AI: Motivation and Design of QSP‑Copilot — Ali Farnoud & Anuraag Saini (Boehringer Ingelheim)

• Inference of latent process in QSP models — Chris Rackauckas (MIT)

12:10 – 13:40 | Lunch & Poster Session

13:40 – 15:00 | Session 3: Immunology QSP: Actors to Partner with Drugs

Chairs: Dirk Jan Moes (LUMC) & Jeroen Elassaiss-Schaap (PD-value)

• Pediatric QSP models for infliximab Treatment in IBD — Tomoyuki Mizuno (Cincinnati Children's Hospital Medical Center)

• Multi-physiology modeling of the immune system in the era of precision immunotherapy — Keimyung Park (Ulsan National Institute of Science and Technology)

• QSP modeling of the immune response to vaccination — Jeff Sachs (Merck)

15:00 – 16:00 | Coffee Break & Poster Session

16:00 – 17:20 | Session 4: Integrating Micro-Physiological and Organ-on-Chip Systems with QSP

Chairs: Linda Aulin (LACDR) & TBD

• Combining Micro-Physiological Systems and PBPK: Where Are We? — James Hickman

• Modeling Kidney Micro-Physiology: A Sex-Specific Perspective — Aurélie Cartier (Maastricht University)

• Organ-on-Chip Data in Quantitative Systems Toxicology — Carmen Pin (AstraZeneca)

DAY 2: Thursday, April 9, 2026

08:30 – 09:50 | Session 5: Leveraging QSP Approaches for Rare Diseases Drug Development

Chairs: Inaki Troconiz (Navarra) & Susana Neves-Zaph (Sanofi)

• From Mechanistic Understanding to Regulatory Approval: QSP Modeling in cTTP — Cameron McBride (Takeda)

• [topic: Pediatric Rare Diseases] — Luca Marchetti (Centre for Computational and Systems Biology)

09:20 – 09:40 | Session 6: Integrating CNS PBPK and QSP approaches

Chairs: Tingjie Guo (LACDR) & Liesbeth de Lange (LACDR)

• The QSPainRelief model framework- the LeiCNS PBPK and binding kinetic models — Liesbeth de Lange (LACDR)

• The QSPainRelief model framework: the QSP neural circuit models on analgesia and side effects — Athan Spiros (In silico Biosciences)

10:10 – 10:55 | Coffee Break & Poster Session

10:55 – 11:15 | Session 7: Enhancing QSP Through Emerging Computational Methods

Chairs: Cesar Pichardo (Astrazeneca) & Laura Zwep (LACDR)

• Evo-evolutionary modeling of drug resistance — Alexander Anderson (Moffit)

• Continuous infusion sensitivity analysis - new methodology proposed — Wilbert de Witte (ESQlabs)

• KANs for learning ODE-based cancer dynamics — Sepinoud Azimi Rashti (TU Delft)

• Copula models for virtual patient populations — Laura Zwep (LACDR)

12:15 – 13:45 | Lunch

10:55 – 11:15 | Session 8: Integrating Data for Global Health: A Systems Approach in Infection Diseases

Chairs: Rada Savic (UCSF) & Rob van Wijk (LACDR)

• Building Translational Platforms: Integrating Preclinical and Clinical Systems Knowledge to Predict Efficacy in Anti-TB Drug Development — Rada Savic (UCSF)

• Mechanism-Based Models to Link Target-Site Exposures to Parasite and Host Responses for Drugs against Neglected Tropical Diseases — Thomas Dorlo (Uppsala University)

• Systems pharmacology modelling of multimodal data to combat antimicrobial resistance — Gauri Rao (University of Southern California)

• Flash Talk

15:05 – 15:50 | Coffee Break & Poster Session

15:50 – 17:30 | Session 9: QSP in Regulatory Submissions: Success Stories, Opportunities, and Future Vision

Chairs: Britta Wagenhuber (Sanofi) & Andrea Manfrin (MHRA)

• Use of QSP Modeling to Support New Drug Development — Hao Zhu (FDA/CDER)

• Leveraging QSP for Regulatory Submissions in Rare Diseases — Susana Neves-Zaph (Sanofi)

• Moving toward best practices for credibility assessment and reporting of QSP models in regulatory interactions — Blerta Shtylla (Pfizer/ISOP)

• Uncertainty quantification methods for complex models used in drug development and/or regulatory approval — Andrew Hooker (Uppsala University)

• Pannel disuccusion

DAY 3: Friday, April 10, 2026

09:00 – 09:20 | Session 10: QSP-informed individualized patient care

Chairs: Catherijne Knibbe (LACDR) & Anne-Grete Märtson (LACDR)

• Systems understanding to individualize dosing for obese populations — Elke Krekels (Certara)

• Mechanistic Modelling to improve Patient Outcome in Pediatric Oncology — Rick Admiraal (Prinses Maxima Center)

• QSP: what is the future for the clinic? — Andrea Edginton (Waterloo University)

• Panel discussion: Next steps towards QSP-informed individualized patient care

10:20 – 11:05 | Coffee Break & Poster Session

11:05 – 12:25 | Session 11: Future of QSP

Chairs: Coen van Hasselt (LACDR)

• [Talk on future QSP developments – set the scene] — Piet van der Graaf (Certara/LACDR)

• Panel discussion

12:25 – 12:45 | Closing & Awards